Mocetinostat
Sponsors
Mirati Therapeutics Inc., Memorial Sloan Kettering Cancer Center, Sarcoma Alliance for Research through Collaboration, University Health Network, Toronto, Jonsson Comprehensive Cancer Center
Conditions
Carcinoma, Non-Small-Cell LungDiffuse Large B-Cell Lymphoma and Follicular LymphomaLung CancerLymphomaMetastatic LeiomyosarcomaMyelodysplastic SyndromeRelapsed and RefractoryResectable Squamous Cell Carcinoma of Oral Cavity
Phase 1
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
CompletedNCT02018926
Start: 2013-12-31End: 2015-09-30Updated: 2017-09-14
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
TerminatedNCT02282358
Start: 2014-10-31End: 2023-05-26Updated: 2024-03-08
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
WithdrawnNCT02993991
Start: 2017-10-10End: 2017-12-21Updated: 2017-12-29
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Active, not recruitingNCT03220477
Start: 2017-08-04End: 2026-07-31Updated: 2025-08-06
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Active, not recruitingNCT04299113
Start: 2020-05-14End: 2027-05-22Target: 38Updated: 2025-06-26
Phase 2
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
CompletedNCT02236195
Start: 2014-10-31End: 2016-07-31Updated: 2017-09-01
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
CompletedNCT02303262
Start: 2015-11-12End: 2016-12-31Updated: 2019-01-29
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
TerminatedNCT02954991
Start: 2016-11-07End: 2021-11-04Updated: 2024-04-22